BR112017023158A2 - anticorpos anti-ap2 e agentes de ligação de antígeno para tratar distúrbios metabólicos - Google Patents
anticorpos anti-ap2 e agentes de ligação de antígeno para tratar distúrbios metabólicosInfo
- Publication number
- BR112017023158A2 BR112017023158A2 BR112017023158A BR112017023158A BR112017023158A2 BR 112017023158 A2 BR112017023158 A2 BR 112017023158A2 BR 112017023158 A BR112017023158 A BR 112017023158A BR 112017023158 A BR112017023158 A BR 112017023158A BR 112017023158 A2 BR112017023158 A2 BR 112017023158A2
- Authority
- BR
- Brazil
- Prior art keywords
- reduced
- antibodies
- cardiovascular disease
- antigen binding
- binding agents
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 2
- 102000036639 antigens Human genes 0.000 title abstract 2
- 108091007433 antigens Proteins 0.000 title abstract 2
- 239000011230 binding agent Substances 0.000 title abstract 2
- 208000030159 metabolic disease Diseases 0.000 title 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 239000008103 glucose Substances 0.000 abstract 2
- 230000009885 systemic effect Effects 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- 208000004930 Fatty Liver Diseases 0.000 abstract 1
- 108010006519 Molecular Chaperones Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000010706 fatty liver disease Diseases 0.000 abstract 1
- 230000004153 glucose metabolism Effects 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 230000035945 sensitivity Effects 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Reproductive Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Child & Adolescent Psychology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
Abstract
esta invenção está na area de anticorpos anti-ap2 melhorados e agentes de ligação de antígeno, e composições dos mesmos, que alvejam a chaperona lipídica ap2/fabp4 (aludida como ?ap2?) para o uso no tratamento de distúrbios tais como diabete, obesidade, doença cardiovascular, doença hepática gordurosa, e/ou câncer, entre outras. em um aspecto, tratamentos melhorados para distúrbios mediados pela ap2 são divulgados em que a ap2 sérica é alvejada e a atividade biológica de ap2 é neutralizada ou modulada usandos anticorpos monoclonais de ap2 com baixa afinidade de ligação, fornecendo níveis mais baixos de glicose sanguínea no jejum, metabolismo de glicose sistêmica melhorado, sensibilidade à glicose sistêmica aumentada, massa de gordura reduzida, esteatose hepática reduzida, doença cardiovascular reduzida e/ou um risco reduzido de desenvolver doença cardiovascular.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562155217P | 2015-04-30 | 2015-04-30 | |
US201562232148P | 2015-09-24 | 2015-09-24 | |
US201562268257P | 2015-12-16 | 2015-12-16 | |
PCT/US2016/030303 WO2016176656A2 (en) | 2015-04-30 | 2016-04-29 | Anti-ap2 antibodies and antigen binding agents to treat metabolic disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112017023158A2 true BR112017023158A2 (pt) | 2018-07-24 |
Family
ID=56134548
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017023158A BR112017023158A2 (pt) | 2015-04-30 | 2016-04-29 | anticorpos anti-ap2 e agentes de ligação de antígeno para tratar distúrbios metabólicos |
Country Status (17)
Country | Link |
---|---|
US (3) | US10160798B2 (pt) |
EP (1) | EP3288584A2 (pt) |
JP (1) | JP2018515082A (pt) |
KR (1) | KR20170138570A (pt) |
CN (1) | CN107667116A (pt) |
AU (1) | AU2016254215A1 (pt) |
BR (1) | BR112017023158A2 (pt) |
CA (1) | CA2982427A1 (pt) |
CL (1) | CL2017002737A1 (pt) |
CO (1) | CO2017012385A2 (pt) |
EA (1) | EA201792388A1 (pt) |
IL (1) | IL255314A0 (pt) |
MX (1) | MX2017013807A (pt) |
SG (1) | SG11201708323SA (pt) |
TW (1) | TW201702271A (pt) |
UY (1) | UY36663A (pt) |
WO (1) | WO2016176656A2 (pt) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018227200A1 (en) * | 2017-06-09 | 2018-12-13 | President And Fellows Of Harvard College | Method to identify compounds useful to treat dysregulated lipogenesis, diabetes, and related disorders |
WO2019161294A1 (en) * | 2018-02-19 | 2019-08-22 | Kupper Thomas S | Targeting lipid metabolism and free fatty acid (ffa) oxidation to treat diseases mediated by resident memory t cells (trm) |
WO2021226600A2 (en) * | 2020-05-08 | 2021-11-11 | President And Fellows Of Harvard College | Treatment of metabolic disorders through the targeting of a novel circulating hormone complex |
WO2023164727A1 (en) * | 2022-02-28 | 2023-08-31 | University Of Iowa Research Foundation | A-fabp antibodies for diagnosis and treatment of obesity-associated diseases |
Family Cites Families (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3674836A (en) | 1968-05-21 | 1972-07-04 | Parke Davis & Co | 2,2-dimethyl-{11 -aryloxy-alkanoic acids and salts and esters thereof |
US4027009A (en) | 1973-06-11 | 1977-05-31 | Merck & Co., Inc. | Compositions and methods for depressing blood serum cholesterol |
JPS5612114B2 (pt) | 1974-06-07 | 1981-03-18 | ||
US4231938A (en) | 1979-06-15 | 1980-11-04 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
DK149080C (da) | 1980-06-06 | 1986-07-28 | Sankyo Co | Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre |
US4450171A (en) | 1980-08-05 | 1984-05-22 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
US4448784A (en) | 1982-04-12 | 1984-05-15 | Hoechst-Roussel Pharmaceuticals, Inc. | 1-(Aminoalkylphenyl and aminoalkylbenzyl)-indoles and indolines and analgesic method of use thereof |
US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
US5354772A (en) | 1982-11-22 | 1994-10-11 | Sandoz Pharm. Corp. | Indole analogs of mevalonolactone and derivatives thereof |
US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
US4499289A (en) | 1982-12-03 | 1985-02-12 | G. D. Searle & Co. | Octahydronapthalenes |
US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
CA1327360C (en) | 1983-11-14 | 1994-03-01 | William F. Hoffman | Oxo-analogs of mevinolin-like antihypercholesterolemic agents |
US4613610A (en) | 1984-06-22 | 1986-09-23 | Sandoz Pharmaceuticals Corp. | Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives |
US4686237A (en) | 1984-07-24 | 1987-08-11 | Sandoz Pharmaceuticals Corp. | Erythro-(E)-7-[3'-C1-3 alkyl-1'-(3",5"-dimethylphenyl)naphth-2'-yl]-3,5-dihydroxyhept-6-enoic acids and derivatives thereof |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
US4647576A (en) | 1984-09-24 | 1987-03-03 | Warner-Lambert Company | Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis |
WO1986003488A1 (en) | 1984-12-04 | 1986-06-19 | Sandoz Ag | Indene analogs of mevalonolactone and derivatives thereof |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
US4668794A (en) | 1985-05-22 | 1987-05-26 | Sandoz Pharm. Corp. | Intermediate imidazole acrolein analogs |
DK336987D0 (da) | 1987-07-01 | 1987-07-01 | Novo Industri As | Immobiliseringsmetode |
AU598775B2 (en) | 1985-10-25 | 1990-07-05 | Sandoz Ag | Heterocyclic analogs of mevalonolactone |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
FR2596393B1 (fr) | 1986-04-01 | 1988-06-03 | Sanofi Sa | Derives de l'acide hydroxy-3 dihydroxyoxophosphorio-4 butanoique, leur procede de preparation, leur application comme medicament et les compositions les renfermant |
US4681893A (en) | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
GR1000959B (el) | 1987-05-22 | 1993-03-16 | Squibb & Sons Inc | ΑΝΑΣΤΟΛΕΙΣ ΤΗΣ ΡΕΔΟΥΚΤΑΣΗΣ HMG-CοA ΠΟΥ ΠΕΡΙΕΧΕΙ ΦΩΣΦΟΡΟ,ΝΕΑ ΕΝΔΙΑΜΕΣΑ ΚΑΙ ΜΕΘΟΔΟΣ |
US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
US4759923A (en) | 1987-06-25 | 1988-07-26 | Hercules Incorporated | Process for lowering serum cholesterol using poly(diallylmethylamine) derivatives |
GB8719042D0 (en) | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
US4871721A (en) | 1988-01-11 | 1989-10-03 | E. R. Squibb & Sons, Inc. | Phosphorus-containing squalene synthetase inhibitors |
US4924024A (en) | 1988-01-11 | 1990-05-08 | E. R. Squibb & Sons, Inc. | Phosphorus-containing squalene synthetase inhibitors, new intermediates and method |
NO177005C (no) | 1988-01-20 | 1995-07-05 | Bayer Ag | Analogifremgangsmåte for fremstilling av substituerte pyridiner, samt mellomprodukter til bruk ved fremstillingen |
JP2919890B2 (ja) | 1988-11-11 | 1999-07-19 | メディカル リサーチ カウンスル | 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用 |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
GB8907617D0 (en) | 1989-04-05 | 1989-05-17 | Celltech Ltd | Drug delivery system |
FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
CA2082948C (en) | 1990-05-16 | 2000-07-11 | Joseph G. Sodroski | Immunogenic peptides, antibodies and uses thereof relating to cd4 receptor binding |
WO1992002551A1 (en) | 1990-08-02 | 1992-02-20 | B.R. Centre Limited | Methods for the production of proteins with a desired function |
US5177080A (en) | 1990-12-14 | 1993-01-05 | Bayer Aktiengesellschaft | Substituted pyridyl-dihydroxy-heptenoic acid and its salts |
GB9112536D0 (en) | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
GB9120467D0 (en) | 1991-09-26 | 1991-11-06 | Celltech Ltd | Anti-hmfg antibodies and process for their production |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
US5470845A (en) | 1992-10-28 | 1995-11-28 | Bristol-Myers Squibb Company | Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia |
CA2150372C (en) | 1993-01-19 | 2002-08-20 | Nancy L. Mills | Stable oral ci-981 formulation and process of preparing same |
FR2716640B1 (fr) | 1994-02-28 | 1996-05-03 | Procedes Machines Speciales | Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion. |
US5385929A (en) | 1994-05-04 | 1995-01-31 | Warner-Lambert Company | [(Hydroxyphenylamino) carbonyl] pyrroles |
US5620997A (en) | 1995-05-31 | 1997-04-15 | Warner-Lambert Company | Isothiazolones |
WO1997012613A1 (en) | 1995-10-05 | 1997-04-10 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
US5889167A (en) | 1996-05-22 | 1999-03-30 | Merck & Co., Inc. | Synthetic glucagon binding proteins |
US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
GB9812545D0 (en) | 1998-06-10 | 1998-08-05 | Celltech Therapeutics Ltd | Biological products |
TR200100773T2 (tr) | 1998-09-17 | 2001-07-23 | Bristol-Myers Squibb Company | Bir aP2 önleyicisinin ve kombinasyonunun kullanıldığı diyabet tedavi yöntemi |
EP1151092B1 (en) | 1999-02-12 | 2008-12-31 | President And Fellows Of Harvard College | Inhibiting formation of atherosclerotic lesions with afabp antisens nucleic acids |
US6548529B1 (en) | 1999-04-05 | 2003-04-15 | Bristol-Myers Squibb Company | Heterocyclic containing biphenyl aP2 inhibitors and method |
US7390824B1 (en) | 1999-09-07 | 2008-06-24 | Bristol-Myers Squibb Company | Method for treating diabetes employing an aP2 inhibitor and combination |
CA2380443C (en) | 2000-05-26 | 2013-03-12 | Ginette Dubuc | Single-domain antigen-binding antibody fragments derived from llama antibodies |
WO2002098917A2 (en) | 2001-02-12 | 2002-12-12 | Curagen Corporation | Human proteins and nucleic acids encoding same |
EP1414461A4 (en) | 2001-07-13 | 2005-10-26 | Bristol Myers Squibb Co | PYRAZINONE INHIBITORS OF FATTY ACID BINDING PROTEIN AND METHOD |
US6908963B2 (en) | 2001-10-09 | 2005-06-21 | Nektar Therapeutics Al, Corporation | Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith |
US6984645B2 (en) | 2001-11-16 | 2006-01-10 | Bristol-Myers Squibb Company | Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein |
GB0129105D0 (en) | 2001-12-05 | 2002-01-23 | Celltech R&D Ltd | Expression control using variable intergenic sequences |
WO2003074679A2 (en) | 2002-03-01 | 2003-09-12 | Xencor | Antibody optimization |
JP4603894B2 (ja) | 2002-12-03 | 2010-12-22 | ユセベ ファルマ ソシエテ アノニム | 抗体産生細胞を同定するためのアッセイ |
GB0312481D0 (en) | 2003-05-30 | 2003-07-09 | Celltech R&D Ltd | Antibodies |
GB0315450D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
PL1644412T5 (pl) | 2003-07-01 | 2019-01-31 | Ucb Biopharma Sprl | Modyfikowane fragmenty Fab przeciwciała |
GB0411186D0 (en) | 2004-05-19 | 2004-06-23 | Celltech R&D Ltd | Biological products |
WO2007063363A2 (de) | 2005-07-21 | 2007-06-07 | Biovendor Laboratory Medicine, Inc. | Verfahren zur bestimmung der konzentration der adipozytären form des fatty acid binding protein (a-fabp, fabp4, ap2) |
EP2500352A1 (en) | 2005-08-19 | 2012-09-19 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
GB0619291D0 (en) | 2006-09-29 | 2006-11-08 | Ucb Sa | Altered antibodies |
US9056905B2 (en) * | 2007-05-21 | 2015-06-16 | Alderbio Holdings Llc | Antibodies to TNF-α and use thereof |
US7906117B2 (en) * | 2007-05-21 | 2011-03-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever |
EP2195341B1 (en) | 2007-09-26 | 2017-03-22 | UCB Biopharma SPRL | Dual specificity antibody fusions |
KR101161378B1 (ko) | 2008-09-09 | 2012-07-02 | 엘지전자 주식회사 | 백색 반사층을 구비한 박막형 태양전지 모듈 및 그 제조방법 |
WO2010035012A1 (en) | 2008-09-26 | 2010-04-01 | Ucb Pharma S.A. | Biological products |
WO2010057260A1 (en) | 2008-11-20 | 2010-05-27 | Angioblast Systems, Inc. | Method for treating or preventing a pancreatic dysfunction |
JP5984396B2 (ja) * | 2009-03-05 | 2016-09-06 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | 分泌されたaP2およびこれを阻害する方法 |
US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
TW201427658A (zh) | 2012-12-10 | 2014-07-16 | Merck Sharp & Dohme | 藉由投予升糖素受體拮抗劑及膽固醇吸收抑制劑治療糖尿病之方法 |
US9062104B2 (en) * | 2013-03-14 | 2015-06-23 | Alderbio Holdings Llc | Therapeutic use of antibodies to HGF |
CN103665139A (zh) * | 2013-11-29 | 2014-03-26 | 中国药科大学 | 一种脂肪细胞型脂肪酸结合蛋白及其单克隆抗体的制备和应用 |
EA201790377A1 (ru) | 2014-09-16 | 2017-08-31 | Регенерон Фармасьютикалз, Инк. | Антитела к глюкагону и их применения |
-
2016
- 2016-04-29 JP JP2017556973A patent/JP2018515082A/ja not_active Abandoned
- 2016-04-29 BR BR112017023158A patent/BR112017023158A2/pt not_active IP Right Cessation
- 2016-04-29 CN CN201680024952.4A patent/CN107667116A/zh active Pending
- 2016-04-29 US US15/143,162 patent/US10160798B2/en active Active
- 2016-04-29 MX MX2017013807A patent/MX2017013807A/es unknown
- 2016-04-29 AU AU2016254215A patent/AU2016254215A1/en not_active Abandoned
- 2016-04-29 SG SG11201708323SA patent/SG11201708323SA/en unknown
- 2016-04-29 KR KR1020177034758A patent/KR20170138570A/ko unknown
- 2016-04-29 CA CA2982427A patent/CA2982427A1/en not_active Abandoned
- 2016-04-29 TW TW105113624A patent/TW201702271A/zh unknown
- 2016-04-29 WO PCT/US2016/030303 patent/WO2016176656A2/en active Application Filing
- 2016-04-29 EP EP16730052.4A patent/EP3288584A2/en not_active Withdrawn
- 2016-04-29 EA EA201792388A patent/EA201792388A1/ru unknown
- 2016-05-02 UY UY0001036663A patent/UY36663A/es not_active Application Discontinuation
-
2017
- 2017-10-29 IL IL255314A patent/IL255314A0/en unknown
- 2017-10-30 CL CL2017002737A patent/CL2017002737A1/es unknown
- 2017-11-30 CO CONC2017/0012385A patent/CO2017012385A2/es unknown
-
2018
- 2018-11-20 US US16/197,066 patent/US11014979B2/en active Active
-
2021
- 2021-05-21 US US17/327,170 patent/US20220089705A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20160319003A1 (en) | 2016-11-03 |
CA2982427A1 (en) | 2016-11-03 |
CO2017012385A2 (es) | 2018-04-30 |
CN107667116A (zh) | 2018-02-06 |
US20220089705A1 (en) | 2022-03-24 |
AU2016254215A1 (en) | 2017-10-26 |
SG11201708323SA (en) | 2017-11-29 |
IL255314A0 (en) | 2017-12-31 |
TW201702271A (zh) | 2017-01-16 |
MX2017013807A (es) | 2018-03-15 |
US10160798B2 (en) | 2018-12-25 |
EA201792388A1 (ru) | 2018-06-29 |
EP3288584A2 (en) | 2018-03-07 |
KR20170138570A (ko) | 2017-12-15 |
US11014979B2 (en) | 2021-05-25 |
US20190161536A1 (en) | 2019-05-30 |
JP2018515082A (ja) | 2018-06-14 |
UY36663A (es) | 2016-07-29 |
WO2016176656A2 (en) | 2016-11-03 |
WO2016176656A3 (en) | 2016-12-08 |
CL2017002737A1 (es) | 2018-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017023158A2 (pt) | anticorpos anti-ap2 e agentes de ligação de antígeno para tratar distúrbios metabólicos | |
BR112017025297A2 (pt) | anticorpos anti-gitr para diagnóstico do câncer | |
BR112017026467A2 (pt) | uso de exossomos para o tratamento de doença | |
BR112013028779B8 (pt) | proteína de ligação de antígeno ou imunoconjugado, imunoconjugado, composição farmacêutica, e, uso de uma composição | |
BR112012025568A2 (pt) | proteínas de ligação ao tnf-<244>. | |
BR112017005110A2 (pt) | anticorpo monoclonal isolado ou fragmento de ligação ao antígeno do mesmo, molécula isolada de ácido nucleico, composição farmacêutica, e, método para diminuir níveis de glicose no sangue ou para tratar uma condição ou doença. | |
BRPI0821110B8 (pt) | anticorpo de neutralização de anti-nr10/il31ra, composição farmacêutica compreendendo o referido anticorpo e uso do mesmo | |
Geissler et al. | In serum veritas—in serum sanitas? Cell non-autonomous aging compromises differentiation and survival of mesenchymal stromal cells via the oxidative stress pathway | |
BR112018016337A2 (pt) | anticorpos monoclonais da proteína ns1 de vírus antidengue | |
MA40041A (fr) | Anticorps anti-gitr et leurs procédés d'utilisation | |
BR112018074978A2 (pt) | anticorpos para alfa-sinucleína e usos dos mesmos | |
ECSP14001260A (es) | Inmunoligantes biespecificos dirigidos contra tnf e il-17 referencia cruzada a solicitudes relacionadas | |
BR112015000776A2 (pt) | Agentes de ligação à rspo3 e usos dos mesmos | |
BR112012030664A2 (pt) | proteína de ligação de antígeno humanizada, molécula de ácido nucleico, vetor de expressão, célula hospedeira recombinante, métodos para a produção de uma proteína de ligação de antígeno, para tratar um indivíduo afligido com uma doença e para aumentar a massa muscular, aumentar a força muscular, e/ou melhorar a função muscular em um paciente, e, composição farmacêutica. | |
BR112014007484A2 (pt) | molécula de ligação a antígeno de indução de resposta imune a antígeno alvo | |
BR112013017446A2 (pt) | composição, uso de dose baixa de pioglitazona, método de tratar a deterioração cognitiva do tipo de alzheimer em um indivíduo humano, de tratar o declínio cognitivo em um indivíduo humano, de determinar o risco aumentado de desenvolver a deterioração cognitiva do tipo de alzheimer em um indivíduo humano em uma uma idade ou faixa de idade pré-determinadas, de determinar se administrar dose baixa de pioglitazona a um indivíduo humano para o tratamento da deterioração congnitiva do tipo de alzheimer, de retardar o início da doença de alzheimer em um indivíduo em risco de desenvolver a doença alzheimer, de retardar o início da deterioração cognitiva amnésia branda em um indivíduo em risco de desenvolver a doença de alzheimer, de retardar o início da doença de alzheimer pré-clínica em um indivíduo em risco de desenvolver a doença de alzheimer, de retardar o início da doença de alzheimer pródroma em um indivíduo em risco de desenvolver a doença de alzheimer, dose baixa de pioglitazona | |
UY30525A1 (es) | Agentes de union dirigidos cuyo blanco es el pdgfr-alfa y sus usos | |
BR112021022661A2 (pt) | Anticorpos biespecíficos ativáveis compreendendo um ligante entre os dois domínios de ligação que é uma região de dobradiça de imunoglobulina humana, ou uma variante dela, e usos dos mesmos | |
BR112019023990A2 (pt) | Bis-octa-hidrofenantreno carboxamidas e conjugados de proteína das mesmas | |
BR112016018205A8 (pt) | métodos de tratamento de mal de alzheimer, de seleção de pacientes, de identificação de pacientes, de previsão, de otimização da eficácia terapêutica, kit, uso de agente e uso in vitro de agente | |
BR112021014074A2 (pt) | Proteínas de ligação ao antígeno anti-receptor il2 gama | |
BR112014029219A8 (pt) | moléculas de ligação de il-6 | |
BR112019000098A2 (pt) | proteína de fornecimento ao cérebro, método de tratamento e/ou profilaxia de distúrbios cerebrais em mamíferos que possuem ou encontram-se em risco de desenvolver o mencionado distúrbio e método de diagnóstico e/ou detecção de distúrbios cerebrais em mamíferos suspeitos de possuir ou que se encontram em risco de desenvolver o mencionado distúrbio | |
BR112015012708A2 (pt) | anticorpos para bmp-6 | |
BR112021025720A2 (pt) | Conjugados anticorpo-fármaco de fator antitecido e métodos relacionados |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2622 DE 06/04/2021. |